Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its upcoming participation in The Citizens Life Sciences Conference.
The company's senior management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 2:30 p.m. ET. Investors and interested parties can access the live webcast through Terns Pharmaceuticals' investor relations website at http://ir.ternspharma.com.
The presentation will be archived on the company's website for a minimum of 30 days after the event, allowing stakeholders who cannot attend the live session to review the discussion at their convenience.
Terns Pharmaceuticals (Nasdaq: TERN), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti con piccole molecole per malattie gravi come oncologia e obesità, ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference.
Il team di alta dirigenza dell'azienda parteciperà a una conversazione informale prevista per mercoledì 7 maggio 2025 alle 14:30 ET. Investitori e interessati potranno seguire la diretta streaming tramite il sito web delle relazioni con gli investitori di Terns Pharmaceuticals all'indirizzo http://ir.ternspharma.com.
La presentazione sarà archiviata sul sito dell'azienda per almeno 30 giorni dopo l'evento, permettendo a chi non potrà partecipare in diretta di rivedere la discussione quando preferisce.
Terns Pharmaceuticals (Nasdaq: TERN), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos con pequeñas moléculas para enfermedades graves como oncología y obesidad, ha anunciado su próxima participación en The Citizens Life Sciences Conference.
El equipo directivo senior de la compañía participará en una charla informal programada para el miércoles 7 de mayo de 2025 a las 2:30 p.m. ET. Los inversores y partes interesadas podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Terns Pharmaceuticals en http://ir.ternspharma.com.
La presentación quedará archivada en el sitio web de la empresa por un mínimo de 30 días después del evento, permitiendo a quienes no puedan asistir en vivo revisar la discusión a su conveniencia.
Terns Pharmaceuticals (나스닥: TERN)은 종양학 및 비만을 포함한 중증 질환 치료를 위한 소분자 약물 개발에 집중하는 임상 단계 바이오제약 회사로, 곧 개최되는 The Citizens Life Sciences Conference에 참여할 예정임을 발표했습니다.
회사의 고위 경영진은 2025년 5월 7일 수요일 오후 2시 30분(동부시간)에 예정된 담화형 대화에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Terns Pharmaceuticals 투자자 관계 웹사이트(http://ir.ternspharma.com)를 통해 라이브 웹캐스트에 접속할 수 있습니다.
발표 내용은 행사 종료 후 최소 30일간 회사 웹사이트에 아카이브되어, 실시간 참여가 어려운 이해관계자들도 편리한 시간에 내용을 다시 확인할 수 있습니다.
Terns Pharmaceuticals (Nasdaq : TERN), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements à petites molécules pour des maladies graves telles que l'oncologie et l'obésité, a annoncé sa prochaine participation à la Citizens Life Sciences Conference.
L'équipe de direction senior de la société participera à une discussion informelle prévue le mercredi 7 mai 2025 à 14h30 ET. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct via le site web des relations investisseurs de Terns Pharmaceuticals à l'adresse http://ir.ternspharma.com.
La présentation sera archivée sur le site internet de la société pendant au moins 30 jours après l'événement, permettant ainsi aux parties prenantes ne pouvant assister en direct de revoir la discussion à leur convenance.
Terns Pharmaceuticals (Nasdaq: TERN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Wirkstoffen für schwerwiegende Krankheiten wie Onkologie und Adipositas spezialisiert hat, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference angekündigt.
Das Senior-Management-Team des Unternehmens wird an einem Fireside Chat teilnehmen, der für Mittwoch, den 7. Mai 2025, um 14:30 Uhr ET geplant ist. Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website von Terns Pharmaceuticals unter http://ir.ternspharma.com verfolgen.
Die Präsentation wird mindestens 30 Tage nach der Veranstaltung auf der Unternehmenswebsite archiviert, sodass Stakeholder, die nicht live teilnehmen können, die Diskussion jederzeit nachverfolgen können.
- Company has a diversified portfolio focusing on high-value therapeutic areas (oncology and obesity)
- Active investor relations engagement through conference participation indicates strong market communication
- Still in clinical-stage with no commercialized products
- Focused on small-molecule products which may face intense competition in oncology and obesity markets
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET.
A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the event.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
When is Terns Pharmaceuticals (TERN) presenting at The Citizens Life Sciences Conference 2025?
How can I watch Terns Pharmaceuticals' (TERN) Citizens Life Sciences Conference presentation?
What areas of medicine does Terns Pharmaceuticals (TERN) focus on?
Will Terns Pharmaceuticals' (TERN) May 7 presentation be recorded?
What type of company is Terns Pharmaceuticals (TERN)?
